Meridian Bioscience to Present at the H. C. Wainright 22nd Annual Global Investment Conference
Rhea-AI Summary
Meridian Bioscience (NASDAQ: VIVO) will present at the H. C. Wainright 22nd Annual Global Investment Conference on September 14, 2020, at 12:30 PM ET. Jack Kenny, CEO, and Bryan Baldasare, CFO, will lead the presentation. Interested participants can access the live webcast through the Company’s Investor Relations website. Meridian Bioscience specializes in innovative diagnostic products and serves customers in over 70 countries, focusing on areas like gastrointestinal infections and blood lead level testing.
Positive
- None.
Negative
- None.
News Market Reaction – VIVO
In the trading session that priced this news, VIVO gained 2.84%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CINCINNATI, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will present at the H. C. Wainright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 12:30pm ET.
To access the live webcast, go the Events & Presentations section of the Company’s Investor Relations website at https://investor.meridianbioscience.com/. Participants should register several minutes in advance of the event’s start time by following the link provided for the event.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: mbi@meridianbioscience.com